Ceapro gains funding for AccuScreen pre-market trials:
This article was originally published in Clinica
Executive Summary
Edmonton, Canada-based Ceapro Technology has received a Can$250,000 (US$192,500) boost for pre-marketing activities for its AccuScreen diagnostic test for diabetes and pre-diabetes. The funding, provided by AVAC, an Alberta-based non-profit, private investment company, will support AccuScreen development in three markets: workplace health, public health and community health. The test is currently undergoing pre-market assessment trials and is expected to be available in Canada next year.